Eventually, CV and particularly CV-LN may hold promise as potential therapeutic candidates for further investigation in the context of neurodegenerative disorders and AD, possibly through modulation of SIRT1/miRNA-134/GSK3β axis. This evidence concerns the gene SIRT1 and Alzheimer disease.